Myocardial Injury Biomarkers in Newborns with Congenital Heart Disease

Ana Luisa Neves a,b,c,*, Maria Cabral d, Adelino Leite-Moreira b,e, José Monterroso a, Carla Ramalho b,f,g, Hercília Guimarães b,h, Henrique Barros b,d, João T. Guimarães b,d,i, Tiago Henriques-Coelho c,j, José C. Areias a,b,c

a Department of Paediatric Cardiology, São João Hospital, Porto, Portugal
b Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research Centre, Faculty of Medicine, University of Porto, Porto, Portugal
c Department of Paediatrics, Faculty of Medicine, University of Porto, Porto, Portugal
d EPI Unit—Institute of Public Health, University of Porto, Porto, Portugal
e Department of Cardiothoracic Surgery, São João Hospital, Porto, Portugal
f Department of Obstetrics, São João Hospital, Porto, Portugal
g Instituto de Investigação e Inovação em Saúde, Porto, Portugal
h Department of Neonatology, São João Hospital, Porto, Portugal
i Department of Clinical Pathology, São João Hospital, Porto, Portugal
j Department of Paediatric Surgery, São João Hospital, Porto, Portugal

Received Mar 31, 2015; received in revised form Oct 22, 2015; accepted Nov 10, 2015
Available online 2 April 2016

Key Words
cardiac biomarkers; congenital heart disease; echocardiography; outcome

Background: Troponin I, myoglobin, and creatine kinase-MB mass (CK-MB) are biomarkers of cardiomyocyte injury widely used in the management of adult patients. The role of these biomarkers in newborns is still not established. The purpose of this study was to evaluate the value of cardiac injury biomarkers in newborns with congenital heart disease.

Methods: From August 2012 to January 2014, 34 newborns with a prenatal diagnosis of congenital heart disease were admitted consecutively to a neonatal intensive care unit. As controls, 20 healthy newborns were recruited. Plasma levels of cardiac biomarkers (troponin I, myoglobin, and CK-MB) were evaluated, and echocardiography was performed to evaluate cardiac function on D 1. Patients were followed during the first 28 days of life and, according to outcome, categorized as surgical or conservative treatment group.

Results: Median (P25–75) levels of CK-MB were higher in patients who underwent cardiac surgery in the neonatal period [7.35 (4.90–13.40) ng/mL] than in patients who were discharged home without surgery [4.2 (2.60–5.90) ng/mL; p = 0.032]. A CK-MB cutoff of ≥ 4.6 ng/mL
1. Introduction

Creatine kinase-MB mass (CK-MB), myoglobin, and cardiac troponins I and T are cardiac injury biomarkers widely used in the management of adult patients. Interest in these cardiac biomarkers in the management of children with congenital heart disease (CHD) has increased; however, there are no current guidelines for their routine use. Reference values for CK-MB and cardiac troponins T and I in healthy neonates have been published. CK-MB levels were elevated in newborns after perinatal and neonatal hypoxia-ischemia, but this elevation was not specific enough to be of clinical value. Myoglobin is a cytoplasmic protein in cardiac and skeletal muscle, and it passes rapidly into circulation after damage to the myocytes. Troponin I was found to be a very sensitive and specific marker of cardiac injury. Troponin I has been used to detect myocardial compromise in newborns with hypoxia and asphyxia, and it was shown to be useful for monitoring myocardial injury in infants of diabetic mothers: an elevated troponin I in infants of diabetic mothers with respiratory distress was a good predictor of hypertrophic cardiomyopathy and left ventricular dysfunction. Troponin I has also been studied in children with left-to-right shunt-induced myocardial injury. Further research is necessary before cardiac injury biomarkers can be used in clinical practice in this age group.

Our hypothesis was that plasma cardiac injury biomarkers might be increased in newborns with CHD, correlated with echocardiographic markers of biventricular function, and useful in the management of these patients.

2. Methods

2.1. Study design and patient population

This is a prospective study of 34 consecutive newborns with a prenatal diagnosis of CHD, who were admitted at the Neonatal Intensive Care Unit of S. João Hospital Center, Porto, Portugal, between August 2012 and January 2014. Additionally, 20 healthy newborns delivered in the same hospital were recruited as controls. Plasma biomarkers were evaluated on Day 1 (with umbilical cord blood after birth or the first sample collected for clinical purposes). The umbilical cord blood was collected after birth following the standard protocol. In the few cases in which it was not possible to collect a cord sample (spasm of the cord or sample coagulation), the peripheral venous blood was collected as soon as a clinical sample for the newborn was performed (the first few hours of life).

Plasma biomarkers evaluated were troponin I, myoglobin, and CK-MB. In all control group newborns except for one, all the biomarkers were measured. In the CHD group, troponin I was available in 33, myoglobin in 26, and CK-MB in 26. The missing values were due to insufficient sample volume.

Plasma biomarkers were compared using all patients’ samples and also using only cord blood samples. Troponin I, myoglobin, and CK-MB were measured by way of chemiluminescent immunoassays using an Architect i2000 automated analyzer (Abbott, Lisboa, Portugal).

CHD cases were subdivided into right ventricle pressure overload (n = 24), left ventricle pressure overload (n = 5), Ebstein disease (n = 2), transposition of great arteries (n = 4), left-to-right shunts (n = 6), and total pulmonary anomalous venous return (n = 1) groups.

The right ventricle pressure overload group included four patients with tetralogy of Fallot, one patient with double outlet right ventricle with pulmonary stenosis, and one patient with pulmonary atresia with ventricular septal defect. The left ventricle pressure overload group included two patients with coarctation of the aorta, one patient with aortic stenosis, one patient with aortic atresia with ventricular septal defect, and one patient with interruption of the aortic arch. The group of transposition of great arteries included two patients with transposition of great arteries and two patients with transposition of great arteries with ventricular septal defects. The left-to-right shunt group included three patients with atrioventricular septal defects, two patients with ventricular septal defects, and one patient with patent ductus arteriosus (PDA). Two patients were excluded because they did not have a surgical indication (supraventricular tachycardia and a small muscular ventricular septal defect).

Patients were followed during the first 28 days of life (neonatal period) and, according to the outcome, categorized as surgical or conservative treatment group.

Of the 24 patients with CHD with a surgical indication (with a type of CHD expected to require surgery at some point in life), 10 had cardiac surgery in the neonatal period: systemic to pulmonary shunts (n = 3), arterial switch (n = 2), Norwood (n = 1), aortic valvuloplasty (n = 1), pulmonary banding (n = 1), correction of coarctation of
2.2. Echocardiographic imaging

Echocardiography was performed on Day 1, using the General Electric Vivid I. Right ventricular, left ventricular function M-mode, and Doppler and tissue Doppler imaging (TDI) parameters were evaluated using standard techniques. For left ventricle systolic function, the evaluated parameters were left ventricle ejection fraction and mitral valve lateral annulus TDI slope. For right ventricle systolic function, the parameters were tricuspid annular plane systolic excursion and tricuspid valve lateral annulus TDI slope. The mitral TDI E’/A’ was acquired in the lateral side of the mitral valve annulus. Each of TDI early diastolic (E’) and late diastolic (A’) myocardial velocities was measured at the upper lateral annulus of the mitral valve during periods of stable heart rate and stable TDI waveforms. The apical four-chamber view was used; care was taken to align the sample volume as vertically as possible with respect to the cardiac apex, and the ratio E’/A’ was calculated. Cardiac performance evaluation was blinded for blood test results.

2.3. Statistical analysis

Continuous variables were presented as medians (25th–75th percentile) and compared using the Mann–Whitney U test. Proportions were compared through the Chi-square test or Fisher exact test, as appropriate. Receiver operator characteristic curves were used to evaluate troponin I, myoglobin, and CK-MB as potential biomarkers. Assays were deemed to be potentially useful if they carried a c-statistic of ≥ 0.75 (corresponding to ≥ 75% of the graph area encompassed by the curve). For a potentially useful test, a clinically relevant cutoff was identified that would distinguish newborns submitted to surgery from those receiving conservative treatment. Logistic regression models were fitted to estimate the association between biomarker levels and cardiac surgery. The association between biomarkers and echocardiographic parameters was analyzed by Spearman’s rank correlation test. SPSS version 21 (IBM, Armonk, NY, USA) was used for statistical analysis. A p value < 0.05 was considered statistically significant.

This study was approved by the São João Hospital, Porto, Portugal, Ethics Committee, and parents of all participants provided written informed consent. The newborns’ physicians were blinded to the results of the biomarkers. Echocardiography was performed and analyzed blinded for biomarker results and outcome.

### Table 1 Biomarker levels in control and congenital heart disease groups.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Control group</th>
<th>CHD group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troponin (ng/mL)</td>
<td>0.01 (0.01–0.02)</td>
<td>0.01 (0.01–0.04)</td>
<td>0.710</td>
</tr>
<tr>
<td>Myoglobin (ng/mL)</td>
<td>50.95 (34.38–73.65)</td>
<td>58.30 (33.88–80.55)</td>
<td>0.748</td>
</tr>
<tr>
<td>CK-MB (ng/mL)</td>
<td>3.60 (2.70–6.20)</td>
<td>4.60 (3.08–7.60)</td>
<td>0.260</td>
</tr>
</tbody>
</table>

CHD = congenital heart disease; CK-MB = creatine kinase-MB mass.
There was a statistically significant negative correlation (Figure 2) between CK-MB levels and TDI of the mitral valve lateral annulus peak early/late diastolic velocity ratio (MV E'/A'; p = 0.480, p = 0.018). Images of measurement of myocardial diastolic function E' and A' waves are exemplified in Figure 3. There was no correlation between CK-MB and the other echocardiographic parameters that were evaluated. For the ventricular systolic function parameters that were evaluated, the median (P25–75) values were 79.0 (69.2–87.0) for left ventricle ejection fraction, 0.046 (0.032–0.050) for mitral valve lateral annulus TDI slope, 7.66 (7.08–9.93) for tricuspid annular plane systolic excursion, and 0.06 (0.05–0.07) for TDI tricuspid valve slope. In control participants, there was no statistically significant correlation between CK-MB and TDI measurements (p = 0.112, p = 0.680). Myoglobin and troponin I did not correlate with echocardiographic parameters.

### 3.1. Correlation between plasma biomarkers and echocardiographic parameters

Troponin I, myoglobin, and CK-MB were not significantly higher in newborns with CHD than in healthy newborns, suggesting that newborns with a prenatal diagnosis of CHD do not present with ischemia at birth. To date, this is the largest study to be published about cardiac injury period [7.35 (4.90–13.40) ng/mL] than in patients who were discharged home without surgery [4.2 (2.60–5.90) ng/mL, p = 0.032]. Troponin I and myoglobin levels were not significantly different between conservative treatment and surgical groups (Table 4).

#### Table 2 Cardiac injury biomarkers in each group of congenital heart defect.

<table>
<thead>
<tr>
<th></th>
<th>Median n</th>
<th>Troponin (ng/mL)</th>
<th>Myoglobin (ng/mL)</th>
<th>CK-MB (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RVPO</td>
<td>6</td>
<td>0.01</td>
<td>55.90</td>
<td>4.90</td>
</tr>
<tr>
<td>LVPO</td>
<td>5</td>
<td>0.01</td>
<td>55.80</td>
<td>4.20</td>
</tr>
<tr>
<td>Ebstein</td>
<td>2</td>
<td>0.02</td>
<td>94.30</td>
<td>8.90</td>
</tr>
<tr>
<td>TGA</td>
<td>4</td>
<td>0.01</td>
<td>47.20</td>
<td>7.40</td>
</tr>
<tr>
<td>L–R shunt</td>
<td>6</td>
<td>0.01</td>
<td>60.15</td>
<td>2.75</td>
</tr>
<tr>
<td>TAPVR</td>
<td>1</td>
<td>0.01</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

CK-MB = creatine kinase-MB mass; Ebstein = Ebstein disease; L–R shunt = left-to-right shunts; RVPO = left ventricle pressure overload; LVPO = left ventricle pressure overload; TAPVR = total pulmonary anomalous venous return; TGA = transposition of great arteries.

#### Table 3 Demographics of patient’s characteristics—surgical versus conservative treatment groups.

<table>
<thead>
<tr>
<th></th>
<th>Surgical group (n = 10)</th>
<th>Conservative treatment group (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female/male)</td>
<td>3/7</td>
<td>4/10</td>
</tr>
<tr>
<td>Gestational age (wk)</td>
<td>37 (37–40)</td>
<td>38 (38–39)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>3145 (2555–3660)</td>
<td>3165 (2874–3330)</td>
</tr>
<tr>
<td>Apgar score 1 min</td>
<td>9 (8–9)</td>
<td>9 (8–9)</td>
</tr>
<tr>
<td>Apgar score 5 min</td>
<td>10 (8–9)</td>
<td>9 (9–10)</td>
</tr>
</tbody>
</table>

Types of congenital heart defects

<table>
<thead>
<tr>
<th></th>
<th>RVPO</th>
<th>LVPO</th>
<th>Ebstein</th>
<th>TGA</th>
<th>L–R shunt</th>
<th>TAPVR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Ebstein = Ebstein disease; L–R shunt = left-to-right shunts; LVPO = left ventricle pressure overload; RVPO = right ventricle pressure overload; TAPVR = total pulmonary anomalous venous return; TGA = transposition of great arteries.

#### Table 4 Cardiac biomarkers by type of treatment (surgical vs. conservative).

<table>
<thead>
<tr>
<th></th>
<th>Surgical treatment Median (P25–75)</th>
<th>Conservative treatment Median (P25–75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Troponin (ng/mL)</td>
<td>0.01 (0.01–0.03)</td>
<td>0.01 (0.01–0.02)</td>
</tr>
<tr>
<td>Myoglobin (ng/mL)</td>
<td>64.90 (49.35–119.93)</td>
<td>55.00 (32.00–64.30)</td>
</tr>
<tr>
<td>CK-MB (ng/mL)</td>
<td>7.35 (4.90–13.40)</td>
<td>4.2 (2.60–5.90)</td>
</tr>
</tbody>
</table>

* p < 0.05.

CK-MB = creatine kinase-MB mass.
biomarkers’ value in newborns with a broad spectrum of CHD before surgery. Kocylowski et al\textsuperscript{6} evaluated injury markers in postpartum cord blood in 10 newborns with CHD. Troponin T was increased only in two out of 10 newborns with CHD; in CK-MB and myoglobin there were no differences from normal. Liesemer et al\textsuperscript{24} reviewed the use of troponin in pediatric practice; however, in the newborn group (with a variety of diagnosis, including birth asphyxia, respiratory distress syndrome, meconium aspiration, or twin–twin transfusion), outcome analysis was not performed. Troponin has been studied in the postoperative setting with discrepant conclusions. Bottio et al\textsuperscript{25} evaluated...

Figure 1  Receiver operator characteristic curves for CK-MB, troponin, and myoglobin. False positives (1-specificity) were plotted against true positives (sensitivity). A test for which the area under the curve (c-statistic) is \( \geq 0.75 \) was defined as a useful test. AUC = area under the curve; CK-MB = creatine kinase-MB mass.

Figure 2  Correlation of mitral valve annulus \( E'/A' \) (MV \( E'/A' \)) with CK-MB. Spearman correlation coefficient = \(-0.480\), \( p = 0.018\). CK-MB = creatine kinase-MB mass; MV \( E'/A' \) = mitral valve lateral annulus peak early/late diastolic velocity ratio.
troponin in the postoperative period in newborns and children; they concluded that troponin I was a specific and sensitive marker of myocardial injury after cardiac surgery and that it might predict early-hospital outcomes, but it lost prognostic significance over the long term. Bojan et al.\(^2\) suggested that routine monitoring of troponin I after surgery for CHD was not useful in patients younger than 1 year.

CK-MB was elevated in newborns after perinatal and neonatal hypoxia–ischemia, but this elevation was not specific enough to be of clinical value.\(^7\),\(^1\) Some conditions such as perinatal hypoxia–ischemia, type of delivery, Apgar score, and saturation of oxygen may influence cardiac biomarkers. However, no cases of asphyxia were observed in our study. Moreover, cardiac biomarkers did not differ according to the mode of delivery, Apgar score, or patient’s saturation of oxygen.

To date, the present study is the only one to show a correlation between cardiac injury biomarkers and TDI in newborns with CHD. CK-MB was negatively correlated with MV \(E'/A'\). This TDI parameter may be obtained in all CHD and allow us to evaluate the diastolic function of these newborns. Previously, TDI \(E'/A'\) ratio of three ventricular walls was evaluated from fetus to neonate and was increased during the transition from fetal to neonatal circulation.\(^27\)

TDI \(E'/A'\) was previously used in newborns of diabetic mothers, and a significant decrease of the \(E'/A'\) ratio at the tricuspid annulus was found in infants of mothers with pregestational diabetes compared with those with gestational diabetes.\(^28\)

Kim et al.\(^22\) evaluated TDI \(E'/A'\) parameter as a marker of diastolic function and correlated it with brain natriuretic peptide (BNP) levels in a population of liver transplant recipients. TDI has also been used in newborns for each myocardial segment, including peak early diastolic velocity (\(E'\)) and peak late diastolic velocity (\(A'\)), to evaluate postnatal left ventricular diastolic function after fetal aortic valvuloplasty. Mitral annular early diastolic tissue velocity (\(E'\)) was lower in patients with fetal aortic valvuloplasty and those with aortic stenosis than in controls in the neonatal period.\(^21\)

Dubin et al.\(^29\) studied the associations between TDI and NT-proBNP, and concluded that TDI imaging may be more useful than traditional measures of diastolic function in a population of end-stage renal disease.

In neonates with respiratory distress syndrome, there was a statistically significant negative correlation between cardiac troponin T on Day 1 and the fractional shortening measured on the same day; however, there was no statistically significant correlation between left ventricular output and cardiac troponin T across the 3 days.\(^30\) No correlations were found between troponin I and echocardiographic measurements in perinatal asphyxia.\(^31\)

The diagnostic role of troponin T has been studied in a group of newborns with CHD, and troponin T levels in newborns with heart pathology were higher than those in healthy ones. However, troponin T concentrations in patients with CHD were correlated neither with clinical symptoms of heart failure, nor with echocardiographic markers of left ventricular function.\(^32\)

The absence of a correlation between cardiac output and cardiac biomarkers may be because of the presence of a PDA, which would lead to an increased left ventricular output without increasing systemic blood flow.\(^30\),\(^33\) In the presence of a PDA, left ventricular output does not reflect the systemic blood flow.\(^19\)

---

**Figure 3** Tissue Doppler images of (A) myocardial diastolic function (mitral valve lateral annulus \(E'/A'\)) from a healthy newborn, (B) an aortic atresia patient with a ventricular septal defect, (C) transposition of the great arteries, and (D) a tetralogy of Fallot.
The limitations of the present study are the number of participants and the lack of biomarker monitoring over time and postsurgery. CK-MB and myoglobin were different depending on the blood source. The cord blood levels (collected immediately after birth) were lower than the peripheral venous blood levels (collected in the first few hours after birth). This may be explained by the circulatory transition from fetal to neonatal life. In healthy newborns, biomarker concentrations are highest during the first 4 days of life, possibly due to the stress of the birth process and due to adaptation of the neonate to postnatal circulation. In newborns with CHD, this transition process may have even more hemodynamic impact since the ductus closure, the decrease in pulmonary vascular resistance, and the increase in systemic vascular resistance may overload the heart, explaining the higher biomarker levels after birth. An understanding of fetal hemodynamics and the acute and chronic changes that occur with the transition from fetal to newborn circulation are important for the care of the healthy newborns and crucial to the recognition, diagnosis, and management of the newborn with significant CHD. In conclusion, CK-MB levels in the first hours of life are higher in newborns that need neonatal cardiac surgery and may be an indicator of myocardial diastolic function. TDI may be more useful than traditional measures of diastolic function in a population of newborns with CHD. Evaluation of cardiac biomarkers in umbilical cord blood is feasible and may be routinely used as part of the management of newborns with CHD.

Conflicts of interest
The authors have no conflicts of interest to disclose relevant to this article.

Acknowledgments
No external funding was secured for this study.

References


